These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28253985)

  • 21. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression.
    Manczak M; Anekonda TS; Henson E; Park BS; Quinn J; Reddy PH
    Hum Mol Genet; 2006 May; 15(9):1437-49. PubMed ID: 16551656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutics of Alzheimer's disease: Past, present and future.
    Anand R; Gill KD; Mahdi AA
    Neuropharmacology; 2014 Jan; 76 Pt A():27-50. PubMed ID: 23891641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural products against Alzheimer's disease: Pharmaco-therapeutics and biotechnological interventions.
    Dey A; Bhattacharya R; Mukherjee A; Pandey DK
    Biotechnol Adv; 2017; 35(2):178-216. PubMed ID: 28043897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice.
    Dragicevic N; Mamcarz M; Zhu Y; Buzzeo R; Tan J; Arendash GW; Bradshaw PC
    J Alzheimers Dis; 2010; 20 Suppl 2():S535-50. PubMed ID: 20463404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction between NH(2)-tau fragment and Aβ in Alzheimer's disease mitochondria contributes to the synaptic deterioration.
    Amadoro G; Corsetti V; Atlante A; Florenzano F; Capsoni S; Bussani R; Mercanti D; Calissano P
    Neurobiol Aging; 2012 Apr; 33(4):833.e1-25. PubMed ID: 21958963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer's disease without reducing amyloid and tau pathology.
    Isopi E; Granzotto A; Corona C; Bomba M; Ciavardelli D; Curcio M; Canzoniero LM; Navarra R; Lattanzio R; Piantelli M; Sensi SL
    Neurobiol Dis; 2015 Sep; 81():214-24. PubMed ID: 25434488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutics of Neurotransmitters in Alzheimer's Disease.
    Kandimalla R; Reddy PH
    J Alzheimers Dis; 2017; 57(4):1049-1069. PubMed ID: 28211810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitochondrial Dysfunction Triggers Synaptic Deficits via Activation of p38 MAP Kinase Signaling in Differentiated Alzheimer's Disease Trans-Mitochondrial Cybrid Cells.
    Yu Q; Du F; Douglas JT; Yu H; Yan SS; Yan SF
    J Alzheimers Dis; 2017; 59(1):223-239. PubMed ID: 28598851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitochondrial Perturbation in Alzheimer's Disease and Diabetes.
    Akhter F; Chen D; Yan SF; Yan SS
    Prog Mol Biol Transl Sci; 2017; 146():341-361. PubMed ID: 28253990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A paradigm shift for evaluating pharmacotherapy for Alzheimer's disease: the 10-patient screening protocol.
    Weinstein JD; Gonzalez ER; Egleton RD; Hunt DA
    Consult Pharm; 2013 Jul; 28(7):443-54. PubMed ID: 23835462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer's Disease.
    Guo L; Tian J; Du H
    J Alzheimers Dis; 2017; 57(4):1071-1086. PubMed ID: 27662318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice.
    Xie Y; Tan Y; Zheng Y; Du X; Liu Q
    J Biol Inorg Chem; 2017 Aug; 22(6):851-865. PubMed ID: 28502066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitochondrial dysfunction in Alzheimer's disease: Therapeutic implications of lithium.
    Singulani MP; De Paula VJR; Forlenza OV
    Neurosci Lett; 2021 Aug; 760():136078. PubMed ID: 34161823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitochondria-Targeted Therapeutics for Alzheimer's Disease: The Good, the Bad, the Potential.
    Mi Y; Qi G; Brinton RD; Yin F
    Antioxid Redox Signal; 2021 Mar; 34(8):611-630. PubMed ID: 32143551
    [No Abstract]   [Full Text] [Related]  

  • 35. Mitochondria in Excitatory and Inhibitory Synapses have Similar Susceptibility to Amyloid-β Peptides Modeling Alzheimer's Disease.
    Amorim JA; Canas PM; Tomé AR; Rolo AP; Agostinho P; Palmeira CM; Cunha RA
    J Alzheimers Dis; 2017; 60(2):525-536. PubMed ID: 28869472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beneficial Effect of Astragaloside on Alzheimer's Disease Condition Using Cultured Primary Cortical Cells Under β-amyloid Exposure.
    Chang CP; Liu YF; Lin HJ; Hsu CC; Cheng BC; Liu WP; Lin MT; Hsu SF; Chang LS; Lin KC
    Mol Neurobiol; 2016 Dec; 53(10):7329-7340. PubMed ID: 26696494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alzheimer's pathogenesis and its link to the mitochondrion.
    Simoncini C; Orsucci D; Caldarazzo Ienco E; Siciliano G; Bonuccelli U; Mancuso M
    Oxid Med Cell Longev; 2015; 2015():803942. PubMed ID: 25973139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond amyloid: the future of therapeutics for Alzheimer's disease.
    Lane RF; Shineman DW; Steele JW; Lee LB; Fillit HM
    Adv Pharmacol; 2012; 64():213-71. PubMed ID: 22840749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rethinking Alzheimer's disease therapy: are mitochondria the key?
    Ankarcrona M; Mangialasche F; Winblad B
    J Alzheimers Dis; 2010; 20 Suppl 2():S579-90. PubMed ID: 20463405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitochondria in aging and Alzheimer's disease.
    Crouch PJ; Cimdins K; Duce JA; Bush AI; Trounce IA
    Rejuvenation Res; 2007 Sep; 10(3):349-57. PubMed ID: 17708691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.